How subvisible particles become invisible-relevance of the refractive index for protein particle analysis

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1434-1446

  Zölls, Sarah ^a,b   Gregoritza, Manuel ^a,b   Tantipolphan, Ruedeeporn ^a   Wiggenhorn, Michael ^a   Winter, Gerhard ^b   Friess, Wolfgang ^b   Hawe, Andrea ^a  

^a Coriolis Pharma ^*  (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biopharmaceuticals; Characterization; Formulation; Image analysis; Light scattering analysis; Particle size; Protein aggregation; Protein formulation; Proteins; Refractive index

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PROTEIN; RITUXIMAB;

ARTICLE; DRUG FORMULATION; IMAGE ANALYSIS; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; REFRACTION INDEX; REFRACTOMETER;

EID: 84876340793     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23479     Document Type: Article

References (44)

1. Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A, Nikolai T, Novak J, Ragheb J, Simak J. 2010. Meeting report on protein particles and immunogenicity of therapeutic proteins: Filling in the gaps in risk evaluation and mitigation. Biologicals 38:602-611.
2. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8:E501-E507.
3. Jiskoot W, van Schie RMF, Carstens MG, Schellekens H. 2009. Immunological risk of injectable drug delivery systems. Pharm Res 26:1303-1314.
4. Fradkin AH, Carpenter JF, Randolph TW. 2011. Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100:4953-4964.
5. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. 2012. Classification of protein aggregates. J Pharm Sci 101:493-498.
6. USP<788>, United States Pharmacopeia, USP35-NF30, 2012. Particulate matter in injections, United States Pharmacopeial Convention.
7. Ph.Eur. 2.9.19, Pharmacopoea Europaea, 7th ed., 2010. Particulate contamination: Sub-visible particles. European Directorate For The Quality Of Medicine (EDQM).
8. Kirshner S. 2012. Regulatory expectations for analysis of aggregates and particles. Talk at Workshop on Protein Aggregation and Immunogenicity; Breckenridge, Colorado; July 12, 2012.
9. Narhi LO. 2012. AAPS update on USP expert committee for Sub visible particle analysis. Newsl AAPS Aggregation Biol Relevance Focus Group 3:3-4.
10. Wuchner K, Büchler J, Spycher R, Dalmonte P, Volkin DB. 2010. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 99:3343-3361.
11. Demeule B, Messick S, Shire SJ, Liu J. 2010. Characterization of particles in protein solutions: Reaching the limits of current technologies. AAPS J 12:708-715.
12. Sharma DK, King D, Oma P, Merchant C. 2010. Micro-flow imaging: Flow microscopy applied to sub-visible particulate analysis in protein formulations. AAPS J 12:455-464.
13. Barnard JG, Singh S, Randolph TW, Carpenter JF. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100:492-503.
14. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10:373-381.
15. Zölls S, Tantipolphan R, Wiggenhorn M, Winter G, Jiskoot W, Friess W, Hawe A. 2012. Particles in therapeutic protein formulations, Part 1: Overview of analytical methods. J Pharm Sci 101:914-935.
16. Grover NB, Naaman J, Ben-Sasson S, Doljanski F. 1969. Electrical sizing of particles in suspensions. I. Theory. Biophys J 9:1398-1414.
17. Burg TP, Godin M, Knudsen SM, Shen W, Carlson G, Foster JS, Babcock K, Manalis SR. 2007. Weighing of biomolecules, single cells and single nanoparticles in fluid. Nature 446:1066-1069.
18. Patel AR, Lau D, Liu J. 2012. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. Anal Chem 84(15):6833-6840.
19. Barnard JG, Babcock K, Carpenter JF. 2012. Characterization and quantitation of aggregates and particles in interferon-β products: Potential links between product quality attributes and immunogenicity. J Pharm Sci 102:915-928.
20. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause H-J, Mahler H-C, Meyer BK, Narhi L, Nesta DP, Spitznagel T. 2010. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 99:3302-3321.
21. Huang C-T, Sharma D, Oma P, Krishnamurthy R. 2009. Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 98:3058-3071.
22. Sharma DK, King D, Merchant C. 2011. Reference material development for calibration and verification of image-based particle analyzers. Int J Pharm 416:293-295.
23. Sharma DK, Oma P, Pollo MJ, Sukumar M. 2010. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. J Pharm Sci 99:2628-2642.
24. Ripple DC, Dimitrova MN. 2012. Protein particles: What we know and what we do not know. J Pharm Sci 101:3568-3579.
25. Huygens C. 1690. Traité de la Lumière. 1st ed. Leiden, the Netherlands: Pieter van der Aa.
26. Ripple DC, Wayment JR, Carrier MJ. 2011. Standards for the optical detection of protein particles. APR July/August 90-96.
27. Ojena SM, de Forest PR. 1972. Precise refractive index determination by the immersion method, using phase contrast stage microscopy and the Mettler hot stage. J Forensic Sci Soc 12:315-329.
28. Tecan. 2001. Determination of the light absorption pathlength in microwell plates. Application note, Tecan, Hombrechtikon, Switzerland, 6/2001, pp 1-4.
29. Brown L. 2011. Characterizing biologics using dynamic imaging particle analysis. BioPharm IntAugust s1-8.
30. Pan G, Tse AS, Kesavamoorthy R, Asher SA. 1998. Synthesis of highly fluorinated monodisperse colloids for low refractive index crystalline colloidal arrays. Mater Sci 7863:6518-6524.
31. Groh W, Zimmermann A. 1991. What is the lowest refractive index of an organic polymer? Macromolecules 24:6660-6663.
32. Microparticles, Berlin, Germany, website, accessed January 29, 2013, at: http://www.microparticles.de/eigenschaften.html.
33. Kemper B, Kosmeier S, Langehanenberg P, von Bally G, Bredebusch I, Domschke W, Schnekenburger J. 2007. Integral refractive index determination of living suspension cells by multifocus digital holographic phase contrast microscopy. J Biomed Opt 12:054009.
34. Curl CL, Bellair CJ, Harris T, Allman BE, Harris PJ, Stewart AG, Roberts A, Nugent KA, Delbridge LMD. 2005. Refractive index measurement in viable cells using quantitative phase-amplitude microscopy and confocal microscopy. Cytometry Part A 65:88-92.
35. Hawe A, Friess W. 2007. Stabilization of a hydrophobic recombinant cytokine by human serum albumin. J Pharm Sci 96:2987-2999.
36. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C, Carpenter JF. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98:94-104.
37. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93:1390-1402.
38. Simponi by Janssen Biotech, Horsham, Pennsylvania, website, accessed January 29, 2013, at: http://www.simponi.com/sites/default/files/pdf/prescribing-information.pdf.
39. Cimzia by UCB, Brussels, Belgium, website, accessed January 29, 2013, at: http://www.cimzia.com/pdf/Prescribing_Information.pdf.
40. Food and Drug Administration, Silverspring, Maryland, website, accessed January 29, 2013, at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_02_B-Abbott-Humira%20Prescribing%20Info.pdf.
41. Amgen, Thousand Oaks, California, website, accessed January 29, 2013, at: http://www.amgen.ca/Enbrel_PM.pdf.
42. Barnard JG, Rhyner MN, Carpenter JF. 2012. Critical evaluation and guidance for using the coulter method for counting subvisible particles in protein solutions. J Pharm Sci 101:140-153.
43. Rhyner MN. 2011. The Coulter principle for analysis of subvisible particles in protein formulations. AAPS J 13:54-58.
44. Mück C. 2002. Analytik von Proteinaggregation mittels Coulter-Prinzip: Vergleich mit der Lichtblockade-Messung. Diploma thesis, Department of Pharmacy, Ludwig Maximilian University Munich/University of Applied Sciences Albstadt-Sigmaringen, Germany.